newsfilter
← Latest News
Business Wire·

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

- On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 - - $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2024; Provides